PT  - JOURNAL ARTICLE
AU  - SHENG-CHUN HUNG
AU  - SHIAN-SHIANG WANG
AU  - CHUN-KUANG YANG
AU  - JIAN-RI LI
AU  - CHEN-LI CHENG
AU  - YEN-CHUAN OU
AU  - HAO-CHUNG HO
AU  - KUN-YUAN CHIU
AU  - CHUAN-SHU CHEN
TI  - Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma
DP  - 2017 Apr 01
TA  - Anticancer Research
PG  - 1875--1883
VI  - 37
IP  - 4
4099  - http://ar.iiarjournals.org/content/37/4/1875.short
4100  - http://ar.iiarjournals.org/content/37/4/1875.full
SO  - Anticancer Res2017 Apr 01; 37
AB  - Aim: To evaluate the efficacy of methotrexate, epirubicin and cisplatin (MEC) or gemcitabine and cisplatin (GC) as adjuvant chemotherapy in advanced upper tract urothelium carcinoma (UTUC). Patients and Methods: From 2002 January to 2008 December, a total of 70 patients with advanced UTUC received radical nephroureterctomy at our Institute with MEC and GC as adjuvant chemotherapy. Disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) among the two groups were evaluated. Results: The MEC (n=30) and GC group (n=40) were compared and showed no significant differences in DFS (p=0.859), CSS (p=0.722) and OS (p=0.691). Positive lymph nodes, preoperative creatinine >1.5, old age, a high ECOG state and low BMI are all the independent risk factors of poor prognosis in advanced UTUC. Conclusion: In patients with UTUC, MEC has a non-inferior efficacy to GC in consideration of cancer recurrence, cancer-specific survival and overall survival.